No Data
No Data
CR Double-Crane Pharmaceutical Unit Gets Drug Registration Certificate for Paliperidone Tablets
China Resources Double-Crane Pharmaceutical (600062.SH): has completed the supporting construction of the synthesis biology from small-scale research to overall industrialization.
China Resources Double-Crane Pharmaceutical (600062.SH) stated on its interactive platform on July 23 that the company has completed the supporting construction of synthetic biology from small-scale research to overall industrialization, and has built a three-level industry system from research and development to pilot plant scale-up and then industrialization. The company has hired a chief scientist and established an R&D team. The small-scale platform has basically completed the construction of core capabilities such as molecular modification, high-throughput screening, strain verification, and enzyme engineering technology. In terms of pilot plant scale-up and industrialization, the focus is on promoting the construction of pilot fermentation workshops and building pilot conversion capabilities. Currently, six key projects of the synthetic biology technology platform are being promoted in an orderly manner, and actively participating in major national specialties.
China Resources Double-Crane Pharmaceutical Completes Phase 1 Trials for Semaglutide Injection for Diabetes Patients
China resources double-crane pharmaceutical (600062.SH): Simcere Glucagon injection completed phase I clinical trial.
China Resources Double-Crane Pharmaceutical (600062.SH) announced that its Sumichrast's Felisyl Injection will be available on July 16, 2024...
China Resources Double-Crane Pharmaceutical (600062.SH): Some products have obtained supplementary drug application approval letters and chemical raw materials market application approval letters.
China Resources Double-Crane Pharmaceutical (600062.SH) announced on July 9th that it has received the Drug Supplement Approval Notice for Aminophylline Injection from the National Medical Products Administration. Its wholly-owned subsidiary, Shuanghe Pharmaceutical (Shangqiu) Co., Ltd., received the Approval Notice for Active Pharmaceutical Ingredient Market Authorization Application from the NMPA.
Investors Aren't Buying China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Earnings
No Data